Agilent Presents Early Career Professor Award to Dr. Gary Patti
News Jul 11, 2017
Agilent Technologies has named Dr. Garry J. Patti, as the recipient of the prestigious 2017 Agilent Early Career Professor Award.
Dr. Patti, Associate Professor, Department of Chemistry Arts and Science, Washington University in St. Louis, was selected for his contributions to the detection of metabolomics changes in whole organisms and their utility for drug discovery, early detection, characterization and surveillance of cancer as well as other diseases and conditions.
Using state-of-the-art mass spectrometers coupled with cutting-edge metabolomic technologies, Dr. Patti’s lab takes a systems-level approach to the study of comprehensive metabolism and identification of specific pathways that are altered in connection with particular phenotypes.
“Agilent is pleased to recognize and support the work of Dr. Patti, who is developing and implementing experimental approaches that advance metabolomics analysis from the lab bench to translational applications in human disease,” said Jack Wenstrand, Director, University Relations and External Research at Agilent.
"Metabolism is one of the most exciting areas in biochemical research. We are honored to have one of the world's best in metabolomics here in our department," said Dr. William Buhro, Chairman, Department of Chemistry; George E. Pake Professor in Arts & Science Washington University in St. Louis.
The annual Agilent Early Career Professor Award was established in 2008. Through this award, Agilent seeks to recognize the achievements of academic researchers in the initial stages of their careers and to support and develop strong collaborative relationships with them at the beginning of their professional lives. This award underscores Agilent's commitment to furthering research through the company's products and services, financial support, and collaborative engagement by Agilent scientists and engineers.
This article has been republished from materials provided by Agilent Technologies. Note: material may have been edited for length and content. For further information, please contact the cited source.
Researchers have figured out precisely why one drug binds to the serotonin receptor 5-HT2BR and activates it to cause heart problems while very similar drugs do not. They've also discovered why a third drug acts like a 5-HT2BR antagonist - it blocks the receptor's activity - while the very well-known similar hallucinogenic drug LSD does not.READ MORE
Each year in the U.S., at least 23,000 people die from infections caused by antibiotic resistant bacteria. Using computer modeling, researchers are developing the means to prevent some of those deaths. One way bacteria develop resistance is by producing pumps that spit out antibiotics, before they can do any damage. The researchers teased out the details of how one antibiotic pump works.READ MORE